The new FDA Commissioner's National Priority Voucher (CNPV) pilot program promises to reduce recipients' application review times from 10-12 months to just 1-2 months. As part of the Trump administration's push for most favored nation (MFN) pricing, drug affordability is one criterion for vouchers, marking FDA's entry into the drug pricing fray. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and counsel Monica Groat explore the voucher awards in detail and discuss how the accelerated review period might affect launch strategies, whether companies with no voucher will be disadvantaged, and potential risks and concerns. Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.

This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200